• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Morgan Stanley initiated coverage on Amicus Therapeutics with a new price target

    9/9/22 7:44:26 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    Morgan Stanley initiated coverage of Amicus Therapeutics with a rating of Equal-Weight and set a new price target of $14.00
    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:59:48 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:58:48 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sblendorio Glenn was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:58:02 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amicus Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

      12/13/24 7:53:22 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Amicus Therapeutics with a new price target

      Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

      9/6/24 7:39:36 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amicus Therapeutics with a new price target

      Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00

      5/30/24 7:51:51 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:00:58 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amicus Therapeutics Inc.

      SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 11:37:23 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:31:54 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care